论文部分内容阅读
目的 观察在吸入皮质激素的基础上联合茶碱控释剂或 β2 激动剂对慢性中度哮喘病人的治疗作用。方法 99例慢性中度哮喘病人随机分为吸入丙酸培氯松 +口服茶碱控释剂组 (T组 )和吸入丙酸培氯松加口服β2 激动剂组 (C组 ) ,疗程均为 8周。记录每日哮喘发作次数、症状评分和测定PEF ;治疗前和每治疗 2周后测定FVC、FEV1。结果 两组病人症状评分、发作次数以及肺功能在治疗后均出现明显改善 ,但两组间无明显差异。比较用药后第 4、6、8周PEF变异率较用药第 1周降低的差值 (△PEF)时 ,发现第 6和 8周T组△PEF明显大于C组。结论 在吸入皮质激素基础上 ,联合应用氨茶碱缓释剂或 β2 激动剂对慢性中度哮喘病人临床症状、肺功能均有明显改善作用。吸入皮质激素联合应用茶碱控释剂对PEF变异率降低幅度大于联合应用 β2 激动剂。
Objective To observe the therapeutic effect of inhaled corticosteroids combined with theophylline controlled release agent or β2 agonist on patients with chronic moderate asthma. Methods Ninety-nine patients with chronic moderate asthma were randomly divided into inhaled fluoxetine + oral theophylline controlled-release group (T group) and inhaled chlortetracycline plus oral β2 agonist group (Group C) 8 weeks. The number of daily asthma attacks, symptom scores, and PEF determination were recorded; FVC and FEV1 were measured before treatment and 2 weeks after each treatment. Results Symptom scores, number of seizures and pulmonary function in both groups were significantly improved after treatment, but there was no significant difference between the two groups. Compared with the difference between the first and the fourth week after treatment (PEF), the △ PEF in the T group at 6th and 8th week was significantly higher than that in the C group. Conclusion On the basis of inhaled corticosteroids, combined application of aminophylline sustained-release agent or β2 agonist on patients with chronic moderate asthma clinical symptoms, pulmonary function were significantly improved. Inhaled corticosteroids combined with theophylline controlled release agent to reduce the rate of variation of PEF is greater than the combined use of β2 agonists.